Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Unum Therapeutics is raising $104,400,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Chuck Wilson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Unum Therapeutics

Unum Therapeutics is a clinical-stage biopharmaceutical company focused on developing curative cell therapies to treat a broad range of cancer patients. Our organization is steeped in a culture of innovation and collaboration. Unum Therapeutics has assembled a stellar team of scientists and experts in drug discovery and development all focused on a singular mission to deliver curative cell therapies to treat more patients with cancer.

To learn more about Unum Therapeutics, visit http://www.unumrx.com/

Contact:
Chuck Wilson, Chief Executive Officer
617-945-5576
https://www.linkedin.com/in/charlesxwilson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved